"11.02 a.m LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome
Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s
Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life
Sciences - New York, NY (United States)"
The data must be quite compelling for Dr. M. to assemble this amazing panel of scientist and technicians, representing very prestigious institutions, to present at the premiere forum for AD about Parkinson's. The dots do connect in the myriad of CNS disorders so why not? In addition to the data I am sure there will be plenty of comentary about improvements in quality of life for those lucky participants not on placebo. This should once and for all put to bed any doubts that Anavex 2-73 is the real deal and it is destined to become the SOC for many of the CNS diseases, if not all, for which today there is very little hope for the expanding population of sufferers.
From the investment stand point I believe that from here forward upward is the trend, albeit with the usual pull backs. I have often thought some of the PPS projections by some of our fellow longs on this board were just pipe dreams. I no longer feel that way and expect that in the next 2-5 years Anavex will be one of the top pharmaceuticals in regards to market capitalization. The sky is the limit fellow longs.
